EP1545489A1 - Traitement de la depression consecutive a la douleur - Google Patents

Traitement de la depression consecutive a la douleur

Info

Publication number
EP1545489A1
EP1545489A1 EP03748971A EP03748971A EP1545489A1 EP 1545489 A1 EP1545489 A1 EP 1545489A1 EP 03748971 A EP03748971 A EP 03748971A EP 03748971 A EP03748971 A EP 03748971A EP 1545489 A1 EP1545489 A1 EP 1545489A1
Authority
EP
European Patent Office
Prior art keywords
pain
depression
milnacipran
serotonin
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03748971A
Other languages
German (de)
English (en)
Other versions
EP1545489A4 (fr
Inventor
Srinivas G. Rao
Jay D. Kranzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Publication of EP1545489A1 publication Critical patent/EP1545489A1/fr
Publication of EP1545489A4 publication Critical patent/EP1545489A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention is in the field of treating atypical depression associated with a chronic pain state.
  • Chronic pain is thought to result in a high incidence of clinical depression with some estimates suggesting that almost two thirds of patients with chronic non-malignant pain have coexisting symptoms of depression or anxiety.
  • One problem in treating chronic pain is that little is known about what causes the pain state. Acute pain occurs when an individual experiences an acute injury. Chronic pain is more complex because it often occurs in the absence of any ongoing illness or disease and is often intractable using conventional analgesics. Chronic pain usually occurs following an acute injury, but continues for an unknown reason after the injured area has healed. Chronic pain can also be caused by an ongoing condition like Chronic Fatigue Syndrome (CFS), Fibromyalgia syndrome (FMS), arthritis, or an illness like cancer or multiple sclerosis. The cause of pain cannot be removed or treated and the pain itself cannot be relieved.
  • CFS Chronic Fatigue Syndrome
  • FMS Fibromyalgia syndrome
  • arthritis or an illness like cancer or multiple sclerosis. The cause of pain cannot be removed or treated and the pain itself cannot be relieved.
  • Depression refers to an abnormal mood or a collection of symptoms that constitute a psychiatric disorder.
  • Symptoms of depression include disturbances in mood and affect (depressed mood, diminished interest and pleasure in activities), bodily function (weight and appetite changes, psychomotor disturbances, sleep disturbances, fatigue and loss of energy), and cognitive processes (feelings of worthlessness and guilt, concentration difficulties, indecisiveness, thoughts of death or suicide and possibly delusions/hallucinations). These symptoms vary in intensity, duration and frequency and permit classification of depression into different classes.
  • Atypical depression is one type of depressive disorder included in
  • DSM-IV-TR at page 420 about which there has been substantial clinical and research interest. Although at the present time it is not clear how common this diagnosis is in chronic pain patients, there are certainly ⁇ ain patients expressing the characteristics of atypical depression. There are at least two broad types of atypical depression that differ from classically defined depression (Davidson et al. Arch. Gen. Psychiatry, 39, 527-34 (1982); Paykel et al. Psychol. Med, 13,:131-9 (1983); Paykel et al, Arch. Gen. Psychiatry, 39:1041-9 (1982)). One is composed of those depressions accompanied by severe anxiety, and also by phobic symptoms, tension, and pain.
  • atypical depression is characterized by reversed vegetative symptoms, e.g., increased (rather than decreased) appetite, weight, and sleep.
  • Monoamine neurotransmitters have been implicated in the body's response to both pain and depression.
  • Norepinephrine (NE) and Serotonin (5-HT) are monoamine neurotransmitters originating in the brain and projecting diffusely throughout the central nervous system.
  • 5-HT and NE are involved in modulating pain transmission from the spinal cord to the brain and also governing the body's moods and responses to stress. Electrical stimulation of these brain regions releases 5-HT and NE and has been reported to produce a deep analgesia in both animals and humans (Akil and Liebeskind Brain Res 94:279-296 (1975)).
  • Tricylic antidepressants are a common class of antidepressant that increase concentrations of NE and 5-HT in the synaptic cleft by blocking reuptake or by inhibiting their metabolism.
  • the increased synaptic availability of NE leads to a delayed desensitization of the ⁇ -Norepinephrine-receptor-coupled adenylate cyclase system.
  • This biochemical action is shared by most clinically effective antidepressant treatments including electro convulsive therapy (Baker and Greenshaw, Cell Molec. Neurobiol, 9:1-44 (1989)).
  • Drugs that selectively inhibit the reuptake of 5-HT are effective treatments for depression.
  • Drugs that block re- uptake inhibitors produce a relapse in depression supporting the importance of this class of drug.
  • Current treatments for depression include tricyclic antidepressants, monoamine oxidase inhibitors, lithium, selective 5-HT reuptake inhibitors, dual reuptake inhibitors and selective NE reuptake inhibitors.
  • Tricyclic antidepressants and selective 5- HT reuptake inhibitors are generally ineffective in treating symptoms of atypical depression such as pain and anxiety and are generally not considered first line therapies (Joyce et al N Z J Psychiatry 36:384-391 (2002); Stewart et al Neuropsychopharmacology 26:237-245 (2002)).
  • monoamine oxidase inhibitors are effective in treating atypical depression, their side effects and prescription-associated dietary restrictions also reduce their suitability as a first-line treatment.
  • Different types of depression can be characterized by the type, intensity and frequency of symptoms, each responding preferentially to different therapeutic drugs.
  • the diversity in the class of monoamine reuptake inhibitors is ideal for treating this broad class of mental illness.
  • Different therapeutic compounds with different binding affinities for each monoamine transporter are ideally suited for therapeutic use and offer the subtle differences that are necessary to treat the numerous types of depression.
  • DSP secondary to pain
  • DSP atypical depressive component of depression secondary to pain
  • DSP depression secondary to pain
  • DSP depression secondary to pain
  • DSP atypical depression secondary to pain
  • the method generally involves administering an effective amount of a monoamine reuptake inhibitor to treat or prevent DSP.
  • a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor (SNRI), or a pharmaceutically acceptable salt thereof is administered.
  • SNRI dual serotonin norepinephrine reuptake inhibitor
  • the most preferred SNRI compounds are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and dual norepinephrine serotonin reuptake inhibitors (NSRIs), wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition.
  • the most preferred compound is milnacipran or a bioequivalent or pharmaceutically acceptable salt thereof.
  • Other preferred compounds are duloxetine, venlfaxine and sibutramine, metabolites, derivatives or a bioequivalent or pharmaceutically acceptable salt of these compounds.
  • a therapeutically effective amount of a non-tricyclic triple reuptake inhibitor ("TRI"), or a pharmaceutically acceptable salt thereof, is administered.
  • TRI non-tricyclic triple reuptake inhibitor
  • the TRI compounds are characterized by their ability to block the reuptake (and, hence, increase central concentrations of) the three primary brain monoamines: serotonin, noradrenaline, and dopamine.
  • the compound is administered in an effective amount to treat symptoms of atypical depression secondary to pain such as anxiety, pain and neurovegetative symptoms.
  • Figure 1 is a bar graph showing the effects of a twice a day (BID) or once a day (QD) adminstration of milnacipran on FMS patient global condition scores. Patients were asked to rate their condition at the end of the treatment on a seven point scale with 1 being worse and 7 being greatly improved. Placebo group scores are also shown (PL).
  • BID twice a day
  • QD once a day
  • Figure 2 is a bar graph showing scores for test FMS subjects using the Beck Depression Index. Scores were taken before the study to establish baseline and at the endpoint of the study to determine change due to treatment. Milnacipran treated subjects once-a-day (QD) or twice-a-day (BID) reported significant improvements over placebo group.
  • QD once-a-day
  • BID twice-a-day
  • Figure 3 is a bar graph showing ITT Response Rate in a binary responder analysis of pain. Scores were derived from data acquired for two weeks before treatment of FMS patients to establish a baseline and for two weeks at the end. Both milnacipran-treated groups demonstrated improved ITT Response Rates over placebo.
  • SNRI dual norepinephrine reuptake inhibitor where norepinephrine reuptake exceeds serotonin reuptake.
  • TRI a compound that blocks the reuptake of 5-HT, NE, and DA I.
  • Disorders to be Treated are widely prevalent psychiatric conditions characterized by the presence of negative affect, with or without mania (e.g., bipolar disorder). A number of sub-types have been described, based upon the presence, chronicity, and severity of specific symptomatology which can determine a patient's treatment. The symptoms of depressive disorders are numerous, and vary in intensity, duration, and frequency. A diagnosis of a depressive disorder can be made when a number of these symptoms have been present for a given period of time.
  • Symptoms of depressive disorders that are not listed in these DSM- IV-TR criteria, but that are often part of a major depressive episode include crying spells, self-pity, hopelessness, irritability, brooding, diminished self- esteem, loss of libido, nihilistic ideas, social withdrawal, memory impairment, feelings of inadequacy, and pessimism (Beck A.T., Depression: clinical, experimental, and theoretical aspects. New York: Hoeber (1967)).
  • Atypical depression is one type of depressive disorder. Some of these patients fulfill DSM-IV-TR criteria for major depression or dysnthymia but manifest their depression with symptoms that are considered atypical; others do not satisfy DSM-IV-TR criteria for a specific mood disorder but appear to be suffering from an atypical depression.
  • Atypical depression is a depressed affect, with the ability to feel better temporarily in response to positive life effect (mood reactivity), plus two or more neurovegetative symptoms that are present for more than about two weeks. There are at least two broad types of atypical depression (Davidson et al. Arch. Gen. Psychiatry, 39, 527-34 (1982); Paykel et al. Psychol.
  • Atypical depression is usually considered a nonmelancholic form of depression meaning the neurovegetative symptoms can be reversed.
  • atypical symptoms must be accompanied by mood reactivity, i.e., "mood regularly improved to at least 50% of normal in response to positive environmental events" (Quitkin et al., Arch. Gen. Psychiatry, 46:787-93 (1989)).
  • depression secondary to pain is intended to refer to a depressive disorder characterized by the co-morbidity of pain and atypical depression.
  • the pain can be chronic pain, neuropathic pain, or a combination thereof.
  • the depression secondary to pain (DSP) can include atypical depression and chronic pain wherein the chronic pain precedes the atypical depression.
  • the depression secondary to pain (DSP) can include atypical depression and chronic pain wherein the atypical depression precedes the chronic pain.
  • the current method of treatment differs from conventional antidepressant treatment because symptoms of atypical depression do not normally respond to tricyclic antidepressants or selective 5-HT reuptake inhibitors.
  • SNRIs have been shown to treat pain and unexpectedly have been found to be effective in treating both the depression and pain associated with this atypical form of depression.
  • Chronic pain continues or recurs over a prolonged period of time, caused by various diseases or abnormal conditions, such as rheumatoid arthritis, CFS or FMS. Chronic pain may be less intense that acute pain.
  • the person with chronic pain does not usually display increased pulse and, rapid perspiration because the automatic reactions to pain cannot be sustained for long periods of time.
  • Others with chronic pain may withdraw from the environment and concentrate solely on their affliction, totally ignoring their family, their friends, and external stimuli. See, Mosby's Medical, Nursing & Allied Health Dictionary, 5 th Edition (1998).
  • DSP can result from chronic pain in the lower back pain, atypical chest pain, headache, pelvic pain, myofascial face pain, abdominal pain, or neck pain.
  • the chronic pain can be caused by a disease or condition such as arthritis, temporal mandibular joint dysfunction syndrome, traumatic spinal cord injury, multiple sclerosis, CFS, irritable bowel syndrome, chronic fatigue syndrome, premenstrual syndrome, multiple chemical sensitivity, hyperventilation, closed head injury, fibromyalgia, rheumatoid arthritis, diabetes, cancer, HIV, or interstitial cystitis.
  • Neuropathic pain is usually associated with inflammation or degeneration of the peripheral nerves, cranial nerves, spinal nerves, or a combination thereof.
  • the pain is typically sharp, stinging, or stabbing.
  • the underlying disorder can result in the destruction of peripheral nerve tissue and can be accompanied by changes in the skin color, temperature, and edema. See, Mosby's Medical, Nursing & Allied Health Dictionary, 5 th Edition (1998); and Stedman's Medical Dictionary, 25 th Edition (1990).
  • the depression secondary to pain can also include atypical depression that includes activity and two or more neurovegetative symptoms such as hypersomnia, increased appetite or weight gain, leaden paralysis, or a long standing pattern of extreme sensitivity to perceived interpersonal rejection; wherein the neurovegetative symptoms are present for more than about two weeks.
  • DRI compounds which inhibit the reuptake of serotonin, noradrenaline, are used to prevent or treat individuals with DSP or symptoms of DSP.
  • Selective norepinephrine (NE) - serotonin (5-HT) reuptake inhibitors are a class of compounds that inhibits the reuptake of both NE and 5- HT where inhibition of reuptake of NE is more than 5-HT.
  • Various techniques are known to determine the norepinephrine (NE) - serotonin (5- HT) reuptalce inhibition of a particular NSRI. In one embodiment, the ratio can be calculated from IC 50 data for NE and 5-HT reuptake inhibition.
  • the selective NSRI will have an NE : 5-HT reuptake inhibition ratio of at least about 1.
  • the selective NSRI can have an NE : 5-HT reuptake inhibition ratio of up to about 50. More specifically, the selective NSRI can have an NE : 5-HT reuptake inhibition ratio of about 1 : 1 to about 50:1. More specifically, the selective NSRI can have an NE : 5-HT reuptake inhibition ratio of about 1 : 1 to about 20:1. More specifically, the selective NSRI can have an NE : 5-HT reuptake inhibition ratio of about 1 : 1 to about 5:1.
  • the NSRI should not substantially increase the risk of seizures.
  • An aminocyclopropane derivative is an aminocyclopropane compound possessing suitable selective norepinephrine (NE) - serotonin (5- HT) reuptake inhibition.
  • NE selective norepinephrine
  • Suitable aminocyclopropane derivatives are disclosed, e.g., in U.S. Patent No. 5,621,142; WO95/22521; Shuto et al, J. Med. Chem., 38:2964-2968, 1995; Shuto et al., J. Med. Chem., 39:4844- 4852, 1996; Shuto et al., J Med. Chem., 41:3507-3514, 1998; and Shuto et al., J. Med. Chem., 85:207-213, 2001.
  • milnacipran One aminocyclopropane derivative is milnacipran, ( ⁇ )-cis-2- (aminomethyl)-N,N-diethyl-l-phenylcyclopropanecarboxa ⁇ mde.
  • the CAS Registry Number is 92623-85-3.
  • Methods of preparing milnacipran are disclosed, e.g., in U.S. Patent No. 4,478,836 and references cited therein.
  • the dextrogyral enantiomer of milnacipran is about twice as active in inhibiting norepinephrine and serotonin reuptake than the racemic mixture, and that the levrogyral enantiomer is much less potent.
  • milnacipran can be administered in enantiomerically pure form (e.g., the pure dextrogyral enantiomer) or as a mixture of dextrogyral and levrogyral enantiomers, such as a racemic mixture.
  • the NE-.5-HT of milnacipran is about 2:1. (See, Moret et al. (1985) Neuropharmacology 24(12): 1211-9.) Palmier et al. (1989). Eur J Clin Pharmacol 37(3): 235-8.
  • Bicifadine is l-(4-methyl-phenyl)-3- azabicyclo[3.1.0]-hexane hydrochloride.
  • the CAS Registry number is 71195-57-8.
  • Bicifadine is an NSRI compound with NMDA receptor antagonist properties. Bicifadine has been described as a non-narcotic analgesic compound (Porter et al Curr Therapeutic Res 30; 1981; Wang et alJClin Pharmacol 1982, 22:160-164).
  • Sibutramine is a TRI compound and blocks the reuptalce of the neurotransmitters dopamine, norepinephrine, and serotonin.
  • the chemical structure of sibutramine is well known in the art. This compound is described in U.S. Patent No. 4,939,175 and Buckett et al,(Prog. Nuero- Psychopharmacol. & Biol. Psychiat 1988 12:575-584).
  • Another preferred compound is venlafaxine; ( ⁇ )-l-[ ⁇ - [dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol hydrochloride.
  • the CAS registry Numbers are 99300-78-4; 93413-69-5. Venlafaxine and synthetic preparations for the same are disclosed, e.g., in U.S. Patent Nos. 4,535,186; 4,761,501; and references cited therein.
  • Another preferred compound is duloxefine; 2-thiophenepropanamine, N-methyl- ⁇ -(l-naphthalenyloxy)-hydrochloride.
  • the CAS Registry Number is 116539-59-4.
  • Tricyclic antidepressants are a well-recognized class of antidepressant compounds and are characterized by a fused tricyclic nucleus. Compounds that are commonly classified as tricyclic antidepressants include imipramine, desipramine, clomipramine, trimipramine, amitriptyline, nortriptyline, doxepin, and protriptyline.
  • Atypical depression is not normally responsive to tricyclic antidepressants and these compounds are not viewed as a first line therapy (Joyce et al NZJ Psychiatry 2002 36:384-391; Stewart et al Neuropsychopharmacology 2002 26:237-245).
  • salts and Derivatives Although described above with reference specific to compounds, one can also utilize enantiomers, stereoisomers, metabolites, derivates and salts of the active compounds. Methods for synthesis of these compounds are known to those skilled in the art.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, and alkali or organic salts of acidic residues such as carboxylic acids.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acid ; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, tolunesulfonic, methanesulfonic, ethane disulfonic, oxalic and isethionic acids.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acid
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric
  • the pharmaceutically acceptable salts can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, PA, 1985, p. 1418).
  • a prodrug is a covalently bonded substance which releases the active parent drug in vivo.
  • Prodrugs are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to yield the parent compound.
  • Prodrugs include compounds wherein the hydroxy or amino group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl or free amino, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups. >
  • a metabolite of the above-mentioned compounds results from biochemical processes by which living cells interact with the active parent drug or other formulas or compounds of the present invention in vivo. Metabolites include products or intermediates from any metabolic pathway. C. Combinations of Active Ingredients
  • Selective norepinephrine (NE) - serotonin (5-HT) reuptalce inhibitors can be administered adjunctively with other active compounds such as antidepressants, analgesics, muscle relaxants, anorectics, stimulants, antiepileptic drugs, and sedative/hypnotics.
  • active compounds such as antidepressants, analgesics, muscle relaxants, anorectics, stimulants, antiepileptic drugs, and sedative/hypnotics.
  • Specific examples include neurontin, pregabalin, pramipexole, L-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, tricyclic antidepressants, codeine, cambamazepine, sibutramine, amphetamine, valium, trazodone and combinations thereof.
  • an anti-DSP compound disclosed herein can be adjunctively administered with drugs that are known or believed to cause (or precipitate) symptoms of atypical depression.
  • a class of medications that are believed to cause atypical depression are antihypertensives: reserpine, ⁇ - blockers such as propranolol, clonidine, methyl-DOPA, and the thiazides. Some of these medications bring about a functional decrease in epinephrine or norepinephrine, neurotransmitters that may be important in the regulation of mood and that may be responsible for the symptoms of depression or the sluggishness that can occur in individuals taking antihypertensives.
  • Additional compounds for treating atypical depression are steroids such as cortisone and prednisone.
  • the active compounds can be formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti- DSP effective amount of a monoamine reuptake inhibitor.
  • the pharmaceutical composition can comprise a pharmaceutically acceptable carrier and an anti-DSP effective amount of an NSRI such as milnacipran or at least two of milnacipran, sibutramine, and an aminocyclopropane derivative.
  • the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders, or in liquid dosage forms, such as elixirs, syrups and suspensions. It can also be administered parenterally, in sterile liquid dosage forms. Additives may also be included in the formulation to enhance the physical appearance, improve stability, and aid in disintegration after administration. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. Typical additives include diluters, binders, lubricants, and disintegrants. Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
  • Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours or days. Sustained release products can also be formulated for implantation or transdermal/transmucosal delivery. Such formulations typically will include a polymer that biodegrades or bioerodes thereby releasing a portion of the active ingredient. The formulations may have the form of microcapsules, liposomes, solid monolithic implants, gels, viscous fluids, discs, or adherent films.
  • Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. They can also be formulated to release the drug substance in a manner to provide medication over a period of time. There are a number of types which include delayed- action tablets in which the release of the drug substance is prevented for an interval of time after administration of until certain physiological conditions exist; repeat-action tablets which periodically release a complete dose of the drug substance to the gastrointestinal fluids; and the extended-release tablets which continuously release increments of the contained drug substance to the gastrointestinal fluids. Compressed tablets may be characterized or described by a number of specifications. These include the diameter size, shape, thickness, weight, hardness, and disintegration time.
  • Film-coated tablets are compressed tablets, which are covered with as thin layer of film or water-soluble material.
  • a number of polymeric substances with film-forming properties may be used.
  • Film coating imparts the same general characteristics as sugar coating with the added advantage of a greatly reduced time period required for the coating operation.
  • Enteric-coated tablets are compressed tablets coated with substances that resist solution in gastric fluid but disintegrate in the intestine. Enteric coatings can be used for tablets containing drug substances which are inactivated or destroyed in the stomach, for those which irritate the mucosa, or as a means of delayed release of the medication.
  • Multiple compressed tablets are compressed tablets made by more than one compression cycle.
  • Layered tablets are prepared by compressing additional tablet granulation on a previously compressed granulation. The operation my be repeated to produce multilayered tablets of two or three layers.
  • Special tablet presses are required to make layered tablets.
  • Press-coated tablets which are also referred to as dry-coated, are prepared by feeding previously compressed tablets into a special tableting machine and compressing another granulation layer around the preformed tablets. They have all the advantages of compressed tablets, i.e., slotting, monogramming, speed of disintegration, etc., while retaining the attributes of sugar-coated tablets in masking the taste of the drug substance in the core tablets.
  • Press-coated tablets can also be used to separate incompatible drug substances; in addition, they can provide a means to give an enteric coating to the core tablets. Both types of multiple-compressed tablets have been widely used in the design of prolonged-action dosage forms.
  • oral compound are compounds that may be orally administered. Although it is preferable that component (a) and component (b) both be administered by the same route (that is, for example, both orally) or dosage form, if desired, they may each be administered by different routes (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously) or dosage forms.
  • the combination products may be formulated such that, although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized.
  • one active ingredient may be enteric coated.
  • enteric coating one of the active ingredients it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines.
  • one active ingredient is coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients.
  • the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine.
  • Still another approach involves the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low-viscosity grade of hydroxypropyl methylcellulose or other appropriate materials as known in the art, in order to further separate the active components.
  • the polymer coating serves to form an additional barrier to interaction with the other component.
  • contact may also be prevented between the individual agents of component (b).
  • Dosage forms wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are blended together and then compressed into a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer.
  • one or more placebo layers may be present such that the placebo layer is between the layers of active ingredients.
  • dosage forms can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or non-perils, which are then enteric coated.
  • enteric coated microtablets, particles, granules or non- perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient.
  • kits useful for the treatment of DSP, related diseases and symptoms include a therapeutically effective amount of a pharmaceutical composition that includes a compound of component (a) and one or more compounds of component (b), in one or more sterile containers.
  • Component (a) and component (b) may be in the same sterile container or in separate sterile containers.
  • the sterile containers of materials may comprise separate containers, or one or more multi-part containers, as desired.
  • Component (a) and component (b) may be separate, or physically combined into a single dosage form or unit as described above.
  • kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art.
  • kit components such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art.
  • Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.
  • water, suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water-soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts, and sodium EDTA are also used.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl- paraben and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, supra, a standard reference text in this field. III. Methods of Use
  • the monoamine reuptake inhibitor compound typically will be administered to an individual expressing symptoms of pain or DSP.
  • the monoamine reuptake inhibitor compound typically will be administered to a patient expressing symptoms of chronic or neuropathic pain even though a diagnosis of DSP may not have yet been made.
  • prophylactic administration may be used to avoid the onset of the symptoms of the underlying disorder, particularly if the symptom manifests cyclically.
  • the therapy is prophylactic with respect to the associated physiological symptoms instead of the underlying indication.
  • the compound could be prophylactically administered prior to bedtime to avoid the sleep disturbances associated with DSP.
  • the compound could be administered prior to recurrence or onset of a particular symptom (for example, pain, or fatigue).
  • Antidepressant medications such as tricyclic antidepressants and selective 5-HT reuptake inhibitors are ineffective in treating symptoms of atypical depression such as anxiety and pain.
  • Antidepressant medications with analgesic properties are candidates for use in this method to treat the atypical depression as well as the pain component associated with it.
  • the pain component of DSP which can be chronic pain or neuropathic pain, can be treated at the same time as the atypical depressive component characteristic of DSP.
  • the administered dosage will vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired.
  • a daily dosage of active ingredient can be expected to be about 0.001 to about 1000 milligrams per kilogram of body weight, with the preferred dose being about 0.1 to about 100 mg/kg, preferably administered several times a day.
  • compositions suitable for administration contain from about 20 mg to about 500 mg of active ingredient per unit.
  • the compound is administered in about 100 mg/day to about 250 mg/day.
  • the compound can be administered up to about 400 mg/day.
  • the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
  • the dosage will preferably be an effective amount to alleviate symptoms of DSP such as pain, anxiety, and neurovegetative symptoms such as fatigue, hypersomnia and hyperphagia.
  • the compounds can be administered to treat pain-associated depression (PAD), and related diseases and symptoms, by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but preferably are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • PID pain-associated depression
  • a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the active compound is preferably administered one or more (e.g., 1, 2, 3, 4, or 5) times per day.
  • compositions can be administered orally, buccally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. In the preferred embodiment the composition is administered orally.
  • Example 1 Therapeutic Effect of Milnacipran on Swim Stress-Induced Muscle Hyperalgesia
  • the swim stress-induced hyperalgesia (SSIH) model displays cutaneous hyperalgesia involving NMDA receptor mechanisms.
  • the SSIH rat model provides a useful animal model of "learned helplessness" where a repeated inescapable stressful event ultimately leads to depression. Chronic pain states develop in these rats resulting from the repeated stressful event.
  • Sprague-Dawley rats weighing (200-300 g) were used in these experiments.
  • Dosage groups consisted of milnacipran in 1, 10 and 30 mg/kg doses as well as uninjected and saline-only controls. Milnacipran was obtained from Pierre-Fabre (France), mixed in normal saline and administered via intraperitoneal injection (i.p.). The stress was applied for 10 mins/day and consisted of sham swim test in 2-3 cm of water (where the animal's feet touched the bottom of the tank), forced swim test in 20 cm of water or no handling at all (i.e. animal left in its cage). Animals were tested before and after the stress to establish baseline and post-stress responses. The parameters were designed to measure muscle hyperalgesia by measuring grip strength (in kgs by algometer) as well as thermal nociception threshold by latency response to hot plate stimulus (in seconds). Results
  • Muscle hyperalgesia was tested by measuring grip strength before and after stress. Swim stress followed by repeated IP injection reduces grip strength that appears to be associated with a muscular allodynia. Saline-only groups displayed decreased grip strength after forced swim stress.
  • Thermal cutaneous hyperalgesia is not responsive to milnacipran (1- 50 mg/kg) and persists unchanged for several days after the stressful event. Muscle hyperalgesia responds well to milnacipran (1-50 mg/kg) reversing the decrease in grip strength seen after forced swim stress. Modulation of cutaneous and muscular nociception can be dissociated in this animal model since they can exist and be pharmacologically affected independently.
  • the SSIH model demonstrates that milnacipran can be administered to prevent the onset of chronic intractable hyperalgesia developing after inescapable swim stress and can be a potential candidate to treat or prevent pain- associated depression.
  • Example 2 Treatment of Depression and Pain in Human Subjects with Once or Twice Daily Milnacipran Treatment.
  • the BDI is a self-administered 21 item self- report scale measuring manifestations of depression. Only subjects completing the 12 week study were included in the analysis.
  • milnacipran which is rapidly absorbed and possesses a half life of approximately 8 hours would be cleared out of the body with only a once-a- day administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes visant à prévenir ou à traiter la dépression atypique consécutive à la douleur (DSP), qui consistent de manière générale à administrer une quantité efficace d'un inhibiteur de réabsorption de monoamines pour traiter ou prévenir les symptômes de la DSP. Dans une forme de réalisation préférée, on administre une quantité thérapeutiquement efficace d'un composé inhibiteur double de réabsorption de sérotonine norépinéphrine (SNRI) d'un type spécifique, ou d'un sel pharmaceutiquement acceptable de celui-ci. Les composés de SNRI préférés sont des SNRI non tricycliques, dans lesquels l'inhibition de réabsorption de la sérotonine est supérieure à celle de la norépinéphrine ; et des SNRI dans lesquels l'inhibition de réabsorption de la norépinéphrine est supérieure à celle de la sérotonine. Le composé préféré est le milnacipran ou un bio-équivalent ou un sel pharmaceutiquement acceptable de celui-ci. D'autres composés préférés sont la duloxetine et la venlafaxine, ou un bio-équivalent ou un sel pharmaceutiquement acceptable de celles-ci. Dans une autre forme de réalisation, on administre une quantité thérapeutiquement efficace d'un composé inhibiteur triple de réabsorption non tricyclique ('TRI') d'un type spécifique, ou un sel pharmaceutiquement acceptable de celui-ci. Les composés TRI sont caractérisés par leur capacité à bloquer la réabsorption (et, de ce fait, à accroître les concentrations centrales) des trois monoamines cérébrales primaires, à savoir la sérotonine, la noradrénaline et la dopamine.
EP03748971A 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur Withdrawn EP1545489A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39867602P 2002-07-24 2002-07-24
US398676P 2002-07-24
US44303503P 2003-01-28 2003-01-28
US443035P 2003-01-28
PCT/US2003/023088 WO2004009069A1 (fr) 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur

Publications (2)

Publication Number Publication Date
EP1545489A1 true EP1545489A1 (fr) 2005-06-29
EP1545489A4 EP1545489A4 (fr) 2006-08-23

Family

ID=30773102

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03748971A Withdrawn EP1545489A4 (fr) 2002-07-24 2003-07-24 Traitement de la depression consecutive a la douleur

Country Status (6)

Country Link
EP (1) EP1545489A4 (fr)
CN (1) CN1671368A (fr)
AU (1) AU2003268020A1 (fr)
CA (1) CA2493490A1 (fr)
MX (1) MXPA05000566A (fr)
WO (1) WO2004009069A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534900B2 (en) * 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN112500361B (zh) * 2020-12-27 2023-05-12 甘肃瀚聚药业有限公司 一种(s)-4-苯基-2-恶唑烷酮的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
WO2003039598A1 (fr) * 2001-11-05 2003-05-15 Cypress Bioscience, Inc. Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (fr) * 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
WO2003039598A1 (fr) * 2001-11-05 2003-05-15 Cypress Bioscience, Inc. Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Martindale" 1999, PHARMACEUTICAL PRESS , LONDON 32 , XP002387013 * page 271, column 2, lines 6-9 * * page 284, column 1 * * page 298, column 1 * * page 1485, column 2 * *
BARKIN R L ET AL: "The management challenges of chronic pain: the role of antidepressants." AMERICAN JOURNAL OF THERAPEUTICS. JAN 2000, vol. 7, no. 1, January 2000 (2000-01), pages 31-47, XP008065677 ISSN: 1075-2765 *
RUOFF G E: "Depression in the patient with chronic pain." THE JOURNAL OF FAMILY PRACTICE. DEC 1996, vol. 43, no. 6 Suppl, December 1996 (1996-12), pages S25-S33 ; dis, XP008065739 ISSN: 0094-3509 *
See also references of WO2004009069A1 *
SPENCER CAROLINE M ET AL: "Milnacipran: A review of its use in depression" DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 56, no. 3, September 1998 (1998-09), pages 405-427, XP008021105 ISSN: 0012-6667 *

Also Published As

Publication number Publication date
WO2004009069A1 (fr) 2004-01-29
EP1545489A4 (fr) 2006-08-23
AU2003268020A1 (en) 2004-02-09
CA2493490A1 (fr) 2004-01-29
MXPA05000566A (es) 2005-08-29
CN1671368A (zh) 2005-09-21

Similar Documents

Publication Publication Date Title
US20040034101A1 (en) Treatment and prevention of depression secondary to pain (DSP)
US7888342B2 (en) Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
EP2322225B1 (fr) Inhibiteurs sélectifs de récaptage de la norépinéphrine et de la sérotonine utilisés dans le traitement du syndrome de la fibromyosite, de l'encéphalo-myélite myalgique et de la douleur
AU2003284005B2 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20080096872A1 (en) Composition for Treatment of Pain Specification
US20140093592A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
PT2701693T (pt) Tapentadol para prevenção e tratamento de depressão e ansiedade
AU2016203771A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
ES2390225T3 (es) Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión
EP1545489A1 (fr) Traitement de la depression consecutive a la douleur
Korn et al. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline
TW200911225A (en) Methods for improving physical function in fibromyalgia
US20060217444A1 (en) Tramadol for the treatment of functional gastrointestinal disorders
AU2012307535A1 (en) Combinations comprising a S1P receptor modulator
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2013201492A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/24 20060101ALI20060712BHEP

Ipc: A61P 25/02 20060101ALI20060712BHEP

Ipc: A61K 31/165 20060101AFI20040211BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060724

17Q First examination report despatched

Effective date: 20061025

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080809